Mosunetuzumab
- Generic Name
- Mosunetuzumab
- Brand Names
- Lunsumio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1905409-39-3
- Unique Ingredient Identifier
- LDJ89SS0YG
- Background
Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as rituximab, in co...
- Indication
Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
- Associated Conditions
- Relapsed or Refractory Follicular Lymphoma
- Associated Therapies
- -
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 242
- Registration Number
- NCT05171647
- Locations
- 🇺🇸
Ironwood cancer and research center, Chandler, Arizona, United States
🇺🇸City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics, Duarte, California, United States
🇺🇸Kaiser Permanente - Irvine, Irvine, California, United States
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 42
- Registration Number
- NCT05169658
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT05155345
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇵🇱Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland
🇵🇱Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM; Oddzial Reumat Rehab i Chorob Wewnetrznych, Poznan, Poland
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT05091424
- Locations
- 🇰🇷
Seoul St Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT04970901
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
CAR-T Followed by Bispecific Antibodies
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT04889716
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Brown University
- Target Recruit Count
- 52
- Registration Number
- NCT04792502
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Lifespan Cancer Insitute, Providence, Rhode Island, United States
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 474
- Registration Number
- NCT04712097
- Locations
- 🇦🇺
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia
🇫🇷Institut Paoli Calmettes, Marseille, France
🇩🇪Medizinische Klinik IV, Hämatologie Universitätsklinikum Gießen, Giessen, Germany
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04313608
- Locations
- 🇦🇺
Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺Monash Health Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT03677141
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of California; Moores Cancer Center, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.